Since anti-TNFi and anti-IL6R therapies did not effectively suppress GM-CSF/GM-CSFRα expression or the GM-CSF-associated landscape, we explored alternative therapeutic strategies to target GM-CSF function using RA blood, synovial tissues, and preclinical models. Here, IL6R is linked to rheumatoid arthritis.